Showing results (531-540 of 550) with videos related to

Sort By:
Pageof 55
Journal of Medicinal Chemistry|September 9, 2000
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitorsB D Dorsey, C McDonough, S L McDaniel, et al.
The British Journal of Surgery|April 5, 2020
Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasionX-P Zhang, K Wang, Y-Z Gao, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|March 2, 2016
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease]Y L Han, Y D Chen, T M Jiang, et al.
Journal of Medicinal Chemistry|November 7, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templatesP E Sanderson, T A Lyle, K J Cutrona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2022
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical TrialXuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|September 2, 2020
[Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)]M M Hu, Q Q Yuan, X S Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|March 6, 2020
[Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group]N Lu, X Wang, C Li, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 18, 2021
[Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)]X M Wang, L Wang, X Wang, et al.
Pageof 55